Sensyne Health’s (SENS) “Buy” Rating Reiterated at Peel Hunt

Peel Hunt reiterated their buy rating on shares of Sensyne Health (LON:SENS) in a research report sent to investors on Thursday.

LON:SENS opened at GBX 166 ($2.17) on Thursday.

Sensyne Health Company Profile

Sensyne Health plc, a healthcare technology company, engages in developing digital health software products in the United Kingdom. Its products include SEND, an early warning system that allows healthcare professionals to record vital sign observations, including blood pressure, pulse rate, oxygen saturation, temperature, respiratory rate, responsiveness, the presence of an oxygen mask, and a reason for concern by the nurse taking the observations; EDGE:COPD, a prescribed digital therapeutic for monitoring chronic obstructive pulmonary disease at home; GDm-Health, a patient-to-clinician system for the management of diabetes in pregnancy; and Support-HF, a digital health software system that underpins a remote patient management service for heart failure patients.

See Also: Earnings Reports

Receive News & Ratings for Sensyne Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensyne Health and related companies with's FREE daily email newsletter.

Leave a Reply